StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Puma Biotech (PBYI) PT Raised to $122 at Barclays on 3Q Report; 'Nerlynx Initial Launch Trend Encouraging, EU Decision in 1Q18'
November 10, 2017 1:10 PM
Barclays raised its price target on Puma Biotech (NASDAQ: PBYI) to $122.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Puma Biotech (PBYI) Publishes 5-Year Analysis of Phase III ExteNET Study
November 14, 2017 5:39 AM
Puma Biotech (PBYI): Solid Start for NERLYNX - Cowen
November 10, 2017 7:49 AM
Puma Biotechnology (PBYI) PT Raised to $142 at Credit Suisse, 'Early Trend Indicators Stronger Trajectory'
November 10, 2017 4:56 AM
Puma Biotechnology (PBYI) PT Raised to $164 at Citi, 'Buy The Dip'
November 10, 2017 4:14 AM
Puma Biotech (PBYI) Tops Q3 EPS by 113c
November 9, 2017 4:16 PM
